Repligen Corp

RGEN

Company Profile

  • Business description

    Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

  • Contact

    41 Seyon Street
    Building 1, Suite 100
    WalthamMA02453
    USA

    T: +1 781 250-0111

    E: [email protected]

    https://www.repligen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    1,778

Stocks News & Analysis

stocks

More gas left in the tank for ASX highflyer

Shares jumped after results and are screening as overvalued.
stocks

Does BHP have a cost problem?

Increasing capital expenditures on Jensen potash project.
stocks

Ahead of Earnings, is Apple stock a buy, a sell, or fairly valued?

Following strong holiday sales and a recent AI deal, here’s what we’re watching for in Apple’s earnings report.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,189.9015.700.17%
CAC 408,130.3512.70-0.16%
DAX 4024,886.2714.44-0.06%
Dow JONES (US)49,098.71285.30-0.58%
FTSE 10010,159.4516.010.16%
HKSE26,765.5216.010.06%
NASDAQ23,501.2465.220.28%
Nikkei 22552,885.25961.62-1.79%
NZX 50 Index13,460.7412.500.09%
S&P 5006,915.612.260.03%
S&P/ASX 2008,860.1015.000.17%
SSE Composite Index4,132.603.56-0.09%

Market Movers